The Vigabatrin REMS Program is required by the FDA to make sure informed risk-benefit choices prior to launching treatment, and to ensure suitable use of vigabatrin while individuals are treated. When vision loss will certainly occur, it is not possible for your health care company to recognize.
It is advised that your healthcare provider test your (or your youngster's) vision prior to or within 4 weeks after beginning SABRIL and at least every 3 months throughout treatment till SABRIL is stopped. If you or your child have any side effect that bothers you or that does not go away, tell your health care service provider.
Tell your doctor if you are expectant or intend to get expectant. If vision testing can not be done, your doctor might proceed recommending SABRIL, however will not be able to expect any type of vision loss. If vision tests are refrained regularly, your doctor might stop suggesting SABRIL for you (or your kid).